Skip Navigation

JNCI Journal of the National Cancer Institute 2000 92(16):1287-1290; doi:10.1093/jnci/92.16.1287
© 2000 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Finn, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Finn, R.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 92, No. 16, 1287-1290, August 16, 2000
© 2000 Oxford University Press

NEWS

Reports Bring Several Changes To IRBs

Robert Finn

A series of new reports, regulations, and recommendations on the conduct of human-subjects research will lead to substantial changes in the inner workings of institutional review boards, which supervise human-subjects research.

This spring, the Department of Health and Human Services’ Office of Inspector General issued one report on the status of its 2-year-old recommendations on protecting human research subjects, another on the U.S. Food and Drug Administration’s oversight of clinical trials, and two others on recruiting subjects for clinical trials. In late May, DHHS Secretary Donna E. Shalala announced several related initiatives. One requires formal training of IRB members and investigators working with human subjects. Another requires increased monitoring of clinical trials. A third is a legislative proposal to allow the FDA to fine investigators and institutions for violations of informed consent rules.

This increased attention to human-subjects protections is no accident, says Paul Root Wolpe, Ph.D., a faculty . . . [Full Text of this Article]

Protecting Human Subjects

Training and Education

Oversight and Sanctions

FDA Oversight


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J Law Med EthicsHome page
M. R. Anderlik and N. Elster
Currents in Contemporary Ethics
J. Law Med. Ethics, June 1, 2001; 29(2): 220 - 228.
[PDF]

Home page
 J Law Med EthicsHome page
M. R. Anderlik and N. Elster
Currents in Contemporary Ethics
J. Law Med. Ethics, March 1, 2001; 29(1): 220 - 228.
[PDF]